Health Care Equipment

Steris

Steris released FY2026 Q4 earnings on May 11 After-Market (EST), actual revenue USD 1.588 B (forecast USD 1.596 B), actual EPS USD 2.24 (forecast USD 2.3533)

Steris released FY2026 Annual Earnings on May 11 After-Market (EST), Actual Revenue: USD 5.936 B (Forecast: USD 5.941 B), Actual EPS: USD 7.93 (Forecast: USD 8.0516)

Steris reports 28% FY26 net income growth and announces $1 billion stock repurchase plan

Steris to Release FY2026 Q4 Earnings on May 11 After-Market EST, Forecast Revenue USD 1.596 B, EPS USD 2.3533

Steris released FY2026 9 Months earnings on February 4 After-Market EST, actual revenue USD 4.348 B, actual EPS USD 5.69

Steris released FY2026 Q3 earnings on February 4 After-Market EST, actual revenue USD 1.496 B (forecast USD 1.481 B), actual EPS USD 1.96 (forecast USD 2.015)

STERIS to Release Q3 2026 Earnings Report

Steris to Release FY2026 Q3 Earnings on February 4 After-Market EST, Forecast Revenue USD 1.481 B, EPS USD 2.015

Mackenzie Financial Corp Reduced Stake in STERIS plc

Neuberger Berman Increases Holdings in STERIS

Julia Madsen sold 5,008 shares in Steris

Steris insiders sold $1,312,096 worth of shares

STERIS plc Stock Hits 52-Week High and Reports Strong Quarterly Earnings

Campbell & CO Investment Adviser LLC Increased Holdings in STERIS plc in Q2

Steris released FY2026 Semi-Annual earnings on November 5 After-Market (EST), actual revenue USD 2.851 B, actual EPS USD 3.74

Steris released FY2026 Q2 earnings on November 5 After-Market EST, actual revenue USD 1.46 B (forecast USD 1.432 B), actual EPS USD 1.94 (forecast USD 1.8583)

Steris Raises Annual Profit Forecast, Shares Up

STERIS plc reports EPS above expectations for Q2

Steris to release FY2026 Q2 earnings report on November 5, After-Market EST, with forecast revenue of USD 1.432 B and EPS of USD 1.8583

Steris PLC Reports Strong Q1 FY26 Earnings and Upgrades Revenue Guidance

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Ordinary dividend (cash)

Ex Date: 2026.06.08 (EST), Cash dividend 0.63 USD

Steris PLC (STE) shares fell 1.79% to $212.11, ending a three-day winning streak amid a poor trading session for the market. Despite this decline, Steris outperformed competitors like Thermo Fisher, Danaher, and Becton Dickinson, which saw larger losses. The stock remains 21.28% below its 52-week high of $269.44 reached on January 16th.

MarketWatch Automated

S&P 500

Dow Jones Industrial Average

Thermo Fisher Scentific

Danaher

Becton Dickinson and

Factset Research

Steris PLC Stock Outperforms Competitors Despite Losses On The Day

SBIO

Steris PLC (STE) shares rose 2.31% to $215.98 on a strong trading day, outperforming competitors like Thermo Fisher Scientific (TMO) and Danaher Corp (DHR). The S&P 500 Index increased by 0.77%, while the Dow Jones Industrial Average rose by 0.75%. Despite the gains, Steris remains 19.84% below its 52-week high of $269.44 reached on January 16. Trading volume was 962,691, surpassing the 50-day average of 790,910.

SPDR S&P Health Equip

ALPS Medical Breakthrough

iShares US Medical Devices

Steris PLC Stock Outperforms Competitors On Strong Trading Day

Steris (NYSE:STE) reported a 7% revenue increase for Q4 2026, with organic growth at 5%. Despite inflation and tariffs affecting gross margins, the company achieved a record 9% revenue growth for the fiscal year. For FY 2027, Steris anticipates 7-8% revenue growth, focusing on organic expansion and strategic acquisitions. The healthcare and life sciences segments each grew by 9%. Management announced a $1 billion share buyback and investments in new facilities to enhance growth and efficiency.

benzinga_article

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

VanEck Biotech ETF

Transcript: Steris Q4 2026 Earnings Conference Call

Steris PLC (STE) shares fell 2.70% to $201.85 on Monday, marking the third consecutive day of losses, despite a positive trading session for the overall market. The stock is currently 25.09% below its 52-week high of $269.44. Competitors like Thermo Fisher Scientific, Danaher Corp., and Becton Dickinson also experienced declines. Trading volume reached 1.0 million, surpassing the 50-day average of 763,874 shares.

Steris PLC Stock Underperforms Monday When Compared To Competitors

STERIS shares are trading higher after the company reported Q4 financial results and issued FY27 adjusted EPS guidance with its midpoint above estimates. Also, the company issued FY27 sales guidance above estimates.

Earnings Watch

Steris | 8-K: FY2026 Q4 Revenue Misses Estimate at USD 1.588 B

Steris(STE.US)